Group 1 - The company, Orbbec Technology Group Co., Ltd., plans to issue A-shares to specific investors in 2025, pending approval from the Shanghai Stock Exchange and the China Securities Regulatory Commission [1][2] - The total number of shares to be issued will not exceed 120,329,952 shares, which is 30% of the company's total share capital before the issuance [1][2] - The issuance price will be no less than 80% of the average trading price of the company's shares over the 20 trading days prior to the pricing date [1][2] Group 2 - The company has outlined its fundraising projects, with a total investment amount of 218,665.62 million yuan, and the funds will be allocated based on project priority if the actual raised amount is less than planned [2][3] - The company emphasizes that the issuance does not constitute a major asset restructuring and will not change the control of the company [2][3] - The company has committed to maintaining a high level of research and development investment, with total R&D expenses amounting to 93,068.52 million yuan during the reporting period [3][5] Group 3 - The company operates in the 3D visual perception technology sector, with applications in areas such as biometric recognition, AIoT, and robotics [2][3] - The company faces various risks, including business operation risks, financial risks, and technology risks, which could impact its profitability and cash flow [2][3] - The company has developed a comprehensive 3D visual perception technology system, focusing on maintaining competitive advantages through continuous technological innovation [3][5]

Core Viewpoint - The legal opinion letter from Beijing King & Wood Mallesons confirms that Orbbec 3D Technology Group Co., Ltd. is authorized to issue A-shares to specific investors in 2025, complying with relevant laws and regulations [1][11][13]. Group 1: Issuance Approval and Authorization - The board of directors approved the issuance plan on April 28, 2025, and the shareholders' meeting ratified it on May 21, 2025, with a validity period of twelve months [12][11]. - The issuance involves A-shares with a par value of RMB 1.00, priced at no less than 80% of the average trading price over the previous 20 trading days [11][19]. Group 2: Issuer's Qualifications - Orbbec is a legally established and validly existing joint-stock company listed in China, with no circumstances requiring termination under laws or regulations [11][19]. - The company meets the conditions for issuance as per the Company Law and Securities Law, with no violations reported in the last three years by its directors or senior management [14][19]. Group 3: Financial and Operational Independence - Orbbec has a complete business system and operates independently, with no significant competition or unfair transactions with its controlling shareholders [20][21]. - The company maintains independent financial management, including separate bank accounts and tax obligations, ensuring financial autonomy [21][20]. Group 4: Major Shareholders and Control - As of the end of the reporting period, the top ten shareholders include major financial institutions, with Huang Yuanhao holding 27.23% directly and controlling a total of 35.73% of the voting rights [23][11]. - Huang Yuanhao's voting rights are enhanced by a special voting mechanism, allowing him to control 64.90% of the voting rights in the company [23][11].

Core Viewpoint - Orbbec Inc. plans to issue A-shares to specific investors in 2025, aiming to enhance its capital structure and support its growth in the 3D visual perception technology sector [2][15][27]. Company Overview - Orbbec Inc. specializes in the design, research, production, and sales of 3D visual perception products, including 3D visual sensors and application devices for both consumer and industrial markets [6][7]. - The company is recognized as one of the few in China to systematically develop and industrialize 3D visual perception technology, holding a comprehensive portfolio of proprietary technologies [7][8]. Financial Data - As of March 31, 2025, the total assets of the company amounted to 323,160.44 million yuan, with total liabilities of 32,727.23 million yuan, resulting in total equity of 290,433.21 million yuan [4]. - The company reported a net profit of 2,416.60 million yuan for the first quarter of 2025, marking a significant improvement compared to previous years [4][5]. Business Operations - The main business operations focus on 3D visual perception technology, with applications in various sectors such as AIoT, robotics, and industrial measurement [6][8]. - The company has established a strong customer base, serving thousands of clients globally and becoming a standard product for leading industry players [8]. Market Position - Orbbec Inc. is among the few global companies capable of mass-producing 3D visual sensors, competing with major players like Apple, Microsoft, and Intel [7][8]. - The company has developed a comprehensive technical system that includes a wide range of technology routes, ensuring its competitive edge in the rapidly evolving market [8]. Future Prospects - The planned issuance of A-shares is expected to provide the necessary funding for ongoing research and development, particularly in the fields of AI and robotics [15][27]. - The company aims to leverage its technological advancements to capture a larger market share as the demand for 3D visual perception technology continues to grow [8].

Core Viewpoint - Orbbec Inc. plans to issue up to 120,329,952 A-shares to specific investors in 2025, with China International Capital Corporation (CICC) as the lead underwriter [1][2][21]. Group 1: Issuance Details - The company intends to issue no more than 120,329,952 shares of RMB ordinary stock (A-shares) [1]. - CICC has been appointed as the sponsor for this issuance [2][21]. - The issuance is in compliance with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [2][21]. Group 2: Company Overview - Orbbec Inc. is registered in Shenzhen and specializes in 3D sensing technology, optical measurement products, and artificial intelligence-related hardware and software [4][5]. - The company was established on January 18, 2013, and listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 7, 2022 [5][6]. Group 3: Shareholder Structure - As of March 31, 2025, the total share capital of the company is 400,001,000 shares, with 35.73% being restricted shares and 64.27% being freely tradable shares [4][7]. - The top ten shareholders hold a significant portion of the company's shares, with detailed ownership structures provided [4][7]. Group 4: Financial Performance - As of March 31, 2025, the total assets of the company amount to 323,160.44 million RMB, with total liabilities of 32,727.23 million RMB, resulting in total equity of 290,433.21 million RMB [10][11]. - The company reported a revenue of 19,105.82 million RMB for the first quarter of 2025, with a net profit of 2,416.60 million RMB [10][11]. Group 5: Internal Review and Compliance - CICC has conducted thorough due diligence and internal reviews to ensure compliance with all regulatory requirements for the issuance [15][21]. - The internal review process includes multiple layers of checks and balances to maintain the integrity of the issuance process [15][17].

Core Viewpoint - The company, Aobi Zhongguang Technology Group Co., Ltd., has received acceptance from the Shanghai Stock Exchange for its application to issue A-shares to specific investors, marking a significant step towards its fundraising efforts [1][2]. Group 1 - The company submitted its securities issuance application to the Shanghai Stock Exchange on July 31, 2025, which has been deemed complete and in compliance with legal requirements [1]. - The acceptance of the application allows the company to proceed with the review process by the Shanghai Stock Exchange [1]. - The issuance of A-shares is contingent upon approval from the China Securities Regulatory Commission, introducing an element of uncertainty regarding the final outcome [2].

Group 1 - Yabont Chemical signed a 10-year supply strategic agreement with Jiangsu Hengrui Medicine to enhance collaboration in the pharmaceutical supply chain, effective from August 1, 2025 [1] - Wei Hua New Materials plans to acquire controlling interest in Jiangsu Heyutai Chemical to extend its product chain and improve competitiveness, currently in the planning stage [2] - Fujirey received a government subsidy of 2.0074 million yuan, expected to positively impact profits in 2025 [4] Group 2 - Hangzhou Garden won the land use rights for a plot in Yuhang District for 130 million yuan, planning to build a smart ecological design R&D headquarters with a total investment of no more than 450 million yuan [5] - Baotai's clinical trial for BAT5906, a recombinant anti-VEGF monoclonal antibody, received approval for new indications, aiming to accelerate commercialization [6] - Weisheng Information won multiple projects with a total bid amount of 110 million yuan, including significant contracts with Southern Power Grid and State Grid [8] Group 3 - Dong'an Power reported a 27.37% year-on-year increase in engine sales for July, totaling 34,500 units [13] - Hanma Technology's truck sales reached 956 units in July, marking a 42.69% year-on-year increase [14] - Jiangsu Bank's executives received regulatory approval for their positions, effective immediately [15] Group 4 - Chip Origin expects Q2 revenue of 584 million yuan, a 49.90% increase quarter-on-quarter, with significant growth in intellectual property licensing fees [24] - Dream Network Technology plans to establish a high-end equipment industry investment fund with a target fundraising of 2 billion yuan [26] - Hefei Urban Construction and China Real Estate Development won land use rights for a residential plot in Hefei for 980 million yuan [28] Group 5 - Lu Kang Pharmaceutical's subsidiary received a drug registration certificate for a new medication for erectile dysfunction [28] - Lifan Pharmaceutical's Mesalazine enteric-coated tablets received a drug registration certificate for treating ulcerative colitis [29] - Yahu Pharmaceutical's APL-1401 clinical trial for ulcerative colitis showed positive preliminary results [30]

上海证券交易所受理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 证券代码：688322 证券简称：奥比中光 公告编号：2025-062 奥比中光科技集团股份有限公司 关于 2025 年度向特定对象发行 A 股股票申请获得 奥比中光科技集团股份有限公司 董事会 2025 年 8 月 2 日 奥比中光科技集团股份有限公司（以下简称"公司"）于 2025 年 7 月 31 日收到上海证券交易所（以下简称"上交所"）出具的《关于受理奥比中光科技 集团股份有限公司科创板上市公司发行证券申请的通知》（上证科审（再融资） 〔2025〕88 号），上交所依据相关规定对公司报送的科创板上市公司发行证券 的募集说明书及相关申请文件进行了核对，认为该项申请文件齐备，符合法定形 式，决定予以受理并依法进行审核。 公司本次向特定对象发行 A 股股票事项尚需通过上交所审核，并获得中国 证券监督管理委员会（以下简称"中国证监会"）作出同意注册的决定后方可实 施，最终能否通过上交所审核，并获得中国证监会同意注册的决定及其时间尚存 在不确定性。公 ...

证券代码：688322 证券简称：奥比中光 奥比中光科技集团股份有限公司 （深圳市南山区西丽街道松坪山社区高新北一道 88 号奥比科技大厦 2001） 2025 年度向特定对象发行 A 股股票 募集说明书 保荐机构（主承销商） （北京市朝阳区建国门外大街 1 号国贸大厦 2 座 27 层及 28 层） 二〇二五年七月 （申报稿） 奥比中光科技集团股份有限公司 2025 年度向特定对象发行 A 股股票募集说明书 声 明 公司及全体董事、高级管理人员承诺本募集说明书及其他信息披露资料不存在虚 假记载、误导性陈述或重大遗漏，并对其真实性、准确性、完整性承担相应的法律责 任。 本公司控股股东、实际控制人承诺本募集说明书及其他信息披露资料不存在虚假 记载、误导性陈述或重大遗漏，并对其真实性、准确性、完整性承担相应的法律责 任。 公司负责人、主管会计工作负责人及会计机构负责人保证募集说明书中财务会计 资料真实、完整。 中国证监会、上海证券交易所对本次发行所作的任何决定或意见，均不表明其对 注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对本公 司的盈利能力、投资价值或者对投资者的收益作出实质性判断或保 ...

上市保荐书 保荐机构（主承销商） （北京市朝阳区建国门外大街 1 号国贸大厦 2 座 27 层及 28 层） 关于奥比中光科技集团股份有限公司 2025 年度向特定对象发行 A 股股票之 二〇二五年七月 奥比中光科技集团股份有限公司 2025 年度向特定对象发行A股股票之上市保荐书 上海证券交易所： 中国国际金融股份有限公司（以下简称"保荐机构"、"本机构"或"中金公司"） 接受奥比中光科技集团股份有限公司（以下简称"奥比中光"、"发行人"或"公司"） 的委托，就发行人 2025 年度向特定对象发行 A 股股票并在科创板上市事项（以下简称 "本次发行"）出具本上市保荐书。 保荐机构及其保荐代表人根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《证券发行上市保荐业务管理办法》 （以下简称"《保荐办法》"）、《上市公司证券发行注册管理办法》（以下简称"《发行注 册管理办法》"），以及《上海证券交易所科创板股票上市规则》（以下简称"《科创板上 市规则》"）、《上海证券交易所发行上市审核规则适用指引第 2 号——上市保荐书内容与 格式》等法律法规和中国证券 ...

奥比中光科技集团股份有限公司 2024 年度审计报告 6-1-1 目 录 | 一、审计报告 ………………………………………………………………………………………… 第 1一6 页 | | --- | | 二、财务报表 … | | (一) 合并资产负债表 ………………………………………………… 第 7 页 | | (二)母公司资产负债表 | | (三)合并利润表 … | | (四)母公司利润表 ………………………………………………………第 10 页 | | (五) 合并现金流量表 ······················································································· 第 1 1 页 | | （六）母公司现金流量表……………………………………………第 12 页 | | (七) 合并所有者权益变动表…………………………………………………第 13 页 | | (八)母公司所有者权益变动表 ……………………………………………第 1 4 页 | | 三、财务报表附注 | | 四、报告附件 ……………………………………………………………… ...